Kimberly-Clark is acquiring Tylenol maker Kenvue in a US$40-billion deal that would propel the Kleenex producer into the upper ranks of the global consumer health market. The purchase marks a major strategic shift as the company looks to diversify beyond paper and personal care products amid ongoing litigation challenges at Kenvue.
BNN Bloomberg spoke with Nik Modi, co-head of global consumer and retail research at RBC Capital Markets, about why the move came sooner than expected and how it could reshape the industry. Modi said the acquisition is transformational for Kimberly-Clark but will test its ability to execute where many others have stumbled.
Key Takeaways
- Kimberly-Clark will acquire Kenvue for about US$40 billion, a move that would make it one of the world’s top consumer health companies.
- The deal positions Kimberly-Clark to surpass Unilever in global health and wellness sales, trailing only Procter & Gamble.
- RBC’s Nik Modi said the transaction came earlier than expected but offers long-term strategic diversification.
- Kenvue faces ongoing legal and regulatory scrutiny, creating short-term headwinds for investor confidence.
- Kimberly-Clark is also selling its European tissue business as part of a broader transformation aimed at streamlining operations.
Read the full transcript below:
MERELLA: Kimberly-Clark is buying Tylenol maker Kenvue for roughly US$40 billion. The consumer health company said the combination would allow it to surpass Unilever. Here to talk about that is Nik Modi, co-head of global consumer and retail research at RBC Capital Markets. My first question, Nik — is Kimberly-Clark getting a deal by buying Tylenol at this time?
NIK: Yeah, I mean, look, this is something I believe Kimberly-Clark has been wanting to do for quite some time. Obviously, when Kenvue went public, it was in the low 20s, and here we are, Kenvue sitting in the $14 range before this deal was announced. So one could argue they’re getting a good deal. Obviously, there are a lot of headwinds and a lot of reasons why Kenvue’s stock was down at this level, but Kimberly-Clark suggested they did enough due diligence and felt it was a good time to buy at this valuation.
MERELLA: Okay, so it could be, as you mentioned, hard to prop up the Tylenol brand on its own, considering what’s been dealt to it from Washington. What do you think?
NIK: Yeah, I mean, look, our view has been — and you’re already starting to see RFK Jr. back off some of his earlier comments — the science is the science. We’re not scientists, but we speak to a lot as part of our research, and the science is pretty clear that there’s no real, high-probability correlation here. It’s much more of a causation situation. And, you know, every woman is different. So our view is that these are all headlines, and when push comes to shove, nothing really significant will come of this. It reminds me of when I covered the tobacco space — there were all these headlines about class action litigation, and then ultimately, when it went to the Supreme Court, those were struck down. I feel like this is a similar type of parallel.
MERELLA: And just to loop our viewers in — what came out of Washington was a warning about Tylenol for pregnant women, saying it’s linked to autism in children, which, of course, has not been proven, and there are no concrete research reports on that. So, Kimberly-Clark owns well-known household brands. I’m wondering whether Kenvue’s lines will be easily absorbed into the company.
NIK: Yeah, look, execution around integrations is always tough, and the consumer products industry doesn’t have a great track record with large-scale M&A. That said, strategically — putting aside the emotion of what’s happening today and people selling Kimberly-Clark stock because they may not agree — if you think about it, strategically, with this combined entity, they’ll be able to provide products for the entire lifespan of a consumer. From birth with diapers, to aging with incontinence products. The older we get, the more skincare we use, right? Kimberly-Clark didn’t have a skincare business before, but now it does. With this combination, they’ll also have more self-care products. So strategically, it makes a lot of sense. The execution is the question. That’s where we’ll have to see if Kimberly-Clark will be an anomaly and pull off a successful integration, or if they’ll struggle, as many companies do early on.
MERELLA: Okay, and you’ve said it’s a year of historic transformation for the company. What else has Kimberly-Clark been up to?
NIK: Yeah, so they’ve announced this deal, but they’re also selling their European consumer tissue business, which is a big one and gave them a lot of negative exposure to the pulp market. So they’re making a lot of changes. They’ve brought in new executives from outside and upgraded their capabilities. Kimberly-Clark has been very active in recent years, and I think they felt the time was right to make this move.
MERELLA: Okay, so tell me about the competition in the space and how this new deal positions Kimberly-Clark.
NIK: Yeah, I mean, clearly, they’ll be in much faster-growing categories and better able to compete with big players like Procter & Gamble, Colgate, and Unilever, because they’ll have scale across so many categories and regions. I think this will make the combined company much more competitive than if they remained separate. But again, it’s all about execution. On paper, this deal makes sense, but the reality could be very different. That’s the work that needs to be done to make sure it’s executed effectively.
MERELLA: Give me an idea of the synergies you see.
NIK: Yeah, they’ve talked about synergies — there are all types of opportunities. First, I’d say Kenvue was under-earning because it had a very complex organizational structure. Under Kimberly-Clark’s management, they can probably streamline that cost structure — that’s part of the synergy. They’ve talked about close to $2 billion in cost synergies. Then you have overlapping infrastructure, and the ability to leverage scale to get better terms on inputs and with retailers. So there’s a lot of opportunity from this combination on the cost side.
MERELLA: Got it. All right, I do have to leave it there, Nik. I’m out of time. Thank you for your time, appreciate it.
NIK: You bet. Thanks.
MERELLA: Nik Modi is co-head of global consumer and retail research at RBC Capital Markets.
---
This BNN Bloomberg summary and transcript of the Nov. 3, 2025 interview with Nik Modi are published with the assistance of AI. Original research, interview questions and added context was created by BNN Bloomberg journalists. An editor also reviewed this material before it was published to ensure its accuracy and adherence with BNN Bloomberg editorial policies and standards.
